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Clinical pathways outline standardized processes in the delivery of care for a specific disease. Patient journeys
through the healthcare system, though, can deviate substantially from recommended or reference pathways.
Given the positive benefits of clinical pathways, it is important to measure the concordance of patient path-
ways so that variations in health system performance or bottlenecks in the delivery of care can be detected,
monitored, and acted upon. This paper proposes the first data-driven inverse optimization approach to
measuring pathway concordance in any problem context. Our specific application considers clinical pathway
concordance for stage III colon cancer. We apply our novel concordance metric to a real dataset of colon
cancer patients from Ontario, Canada and show that it has a statistically significant association with sur-
vival. Our methodological approach considers a patient’s journey as a walk in a directed graph, where the
costs on the arcs are derived by solving an inverse shortest path problem. The inverse optimization model
uses two sources of information to find the arc costs: reference pathways developed by a provincial cancer
agency (primary) and data from real-world patient-related activity from patients with both positive and
negative clinical outcomes (secondary). Thus, our inverse optimization framework extends existing models
by including data points of both varying “primacy” and “goodness”. Data primacy is addressed through
a two-stage approach to imputing the cost vector, while data goodness is addressed by a hybrid objective
function that aims to both minimize and maximize suboptimality error for different subsets of input data.
Key words : inverse optimization, network flow, clinical pathway concordance, colon cancer, survival
analysis
1. Introduction
Clinical pathways, also known as disease pathways or integrated care pathways, are care plans
outlining standardized processes in the delivery of care for a specific cohort of patients (Campbell
et al. 1998). They prescribe a sequence of steps for managing a clinical process with the aim of
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optimizing patient or population-level outcomes such as survival, cost, and wait times. Clinical
pathways are widely used across a range of medical domains including cancer (Evans et al. 2013,
Schmidt et al. 2018, Ling et al. 2018), mental health (Samokhvalov et al. 2018), and surgical recov-
ery (Van Zelm et al. 2018). With applicability to screening, diagnostic, and treatment processes,
they have been shown to be effective in improving patient survival and satisfaction, wait times,
in-hospital complications, and cost of care (Rotter et al. 2012, Panella et al. 2003, Schmidt et al.
2018). Given the importance of clinical pathways in promoting best practices and standardizing
or streamlining care, there is significant interest in developing quantitative metrics to measure the
concordance of patient-traversed pathways against the recommended pathways, which we will refer
to as reference pathways. Such metrics may assist in monitoring variations in the health system and
across the care continuum, identifying bottlenecks or changes in the delivery of care, and ultimately
providing data-driven evidence to inform health policy decisions. Understanding the root of any
discordance is necessary to fully realize the aforementioned benefits of clinical pathways.
Existing methodologies for measuring similarity between pathways have primarily leveraged
process mining, a family of techniques that connect business process management with data mining
algorithms (Bose and van der Aalst 2010, Adriansyah et al. 2011, Yang et al. 2017, 2016). General
similarity metrics are typically based on edit distance algorithms (van de Klundert et al. 2010,
Forestier et al. 2012, Yan et al. 2018), which compare two processes represented as a sequence of
distinct activities by counting the minimum number of operations needed to transform one into the
other. This type of distance measurement can be weighted, where certain activity deviations are
more heavily penalized, or unweighted. Unweighted approaches implicitly assume all deviations are
equally disadvantageous, which is limiting since different types of discordance will have differential
impact on clinical outcomes. On the other hand, weighted approaches to date have relied on
domain knowledge and expert input to determine the weights, which is subjective and sensitive to
misspecification. The existing approaches in the literature are either unweighted or use subjectively
derived weights. Given these limitations, our focus is on developing a weighted concordance metric
with objectively derived or data-driven weights.
There are two sources of information that can be used to derive weights for a concordance metric:
reference pathways and data from real-world patient-related activity. We argue that reference path-
ways should be the primary information source since they are derived from best available medical
evidence and are designed for specific clinical outcomes. Furthermore, concordance measurement
in a health system is ideally optimized for a hierarchy of outcomes, with clinical outcomes usually
given priority. Thus, it makes sense for reference pathways to be used directly to derive weights for
the concordance metric. Real-world patient activity, in the form of individual patient pathways,
can serve as an important secondary data source to fine tune the weights. However, it should not be
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used as a primary source to determine the weights since there can be significant variation between
individual patient pathways, and outcomes typically depend on many other contributing and con-
founding factors besides pathway concordance. Patients with good outcomes may have undertaken
activities that are not recommended in the reference pathways or that should not be associated
with better outcomes. They may also have missed important activities. Overall, the weights should
maximize concordance when a reference pathway is measured against itself while scoring discordant
pathways lower. The problem of finding such weights can thus be posed naturally as an inverse
optimization problem.
In this paper, our goal is to use inverse optimization to develop a data-driven concordance metric
for measuring clinical pathway concordance that has a validated, statistically significant association
with patient survival. Such a metric can help pinpoint discordant activity in a complex health
system, from geographical regions to individual providers, and therefore support policy makers
in crafting informed, data-driven decisions about health system interventions. To support such
data-driven decision making, we first need a rigorous approach to measuring concordance.
We model a patient’s journey through the healthcare system as a walk in a directed graph
in which each node represents a possible activity that a patient can undertake. Patients incur
“costs” by visiting nodes and traversing arcs through the network, which allows us to model
both the costs associated with undertaking (or missing) certain activities, as well as sequencing
costs for progressing from one activity to the next. A reference pathway can be considered an
optimal solution of an appropriately formulated minimum cost network flow problem, a shortest
path problem in particular. Given that the “forward” problem is a network flow problem, we can
formulate the “inverse” problem tractably using linear programming duality (Ahuja and Orlin
2001). The goal of the inverse optimization model is to find arc costs such that all reference
pathways are optimal for the resulting network. If there does not exist a cost vector that makes
all reference pathways simultaneously optimal, then the costs should be such that a measure of
aggregate error (e.g., optimality gap) is minimized. Once the arc costs are determined, any input
pathway (reference or patient-traversed) can be scored based on the cost of the associated directed
walk through the network. In other words, these arc costs form the weights used in the concordance
metric.
Modern inverse optimization methodologies aim to impute unknown parameters of an optimiza-
tion problem to make observed decisions minimally suboptimal (Troutt et al. 2006, Keshavarz
et al. 2011, Chan et al. 2014, Bertsimas et al. 2015, Aswani et al. 2018, Esfahani et al. 2018, Chan
et al. 2019, Babier et al. 2019). Inverse network flow problems are well-studied in the literature,
but primarily focus on a single, noiseless observed decision for which it is possible to determine
parameters that make the decision exactly optimal (Burton and Toint 1992, Xu and Zhang 1995,
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Zhang et al. 1995, Zhang and Ma 1996, Yang et al. 1997, Burton et al. 1997, Zhang and Cai 1998,
Ahuja and Orlin 2001, 2002). Inverse network flow problems with multiple noisy observations have
received limited attention to date (Farago´ et al. 2003, Zhao et al. 2015). We extend these papers by
introducing a general inverse optimization framework for standard form linear optimization prob-
lems that explicitly accounts for the lower dimensionality of the feasible region due to the equality
constraints corresponding to flow balance. This dimensionality issue also requires modifying how
goodness-of-fit is measured in inverse optimization, which to date has only considered problems
with full dimensional feasible regions (Chan et al. 2019). Finally, unlike many previous papers, we
do not restrict the sign of the cost vector.
For a practical application of our inverse optimization framework, we study clinical pathway
concordance for stage III colon cancer pathways developed by Cancer Care Ontario. Cancer Care
Ontario is the Ontario government’s principal advisor on cancer care. It directs and oversees health-
care funds for hospitals and other cancer care providers, enabling them to deliver high-quality,
timely services and improved access to care. As such, Cancer Care Ontario’s responsibilities include
developing guidelines and standards related to the delivery of cancer care, as well as monitoring
the performance of the cancer system in Ontario, Canada. Colon cancer is one of the most com-
monly diagnosed cancers and a leading cause of death from cancer worldwide for both men and
women (World Cancer Research Fund 2019). In our numerical experiments, we demonstrate how
inverse optimization can be used to learn a cost vector from reference and patient pathways in
an appropriately formulated clinical activity network. We develop both a goodness-of-fit metric
to measure the quality of the inverse optimization solution, as well as a concordance metric to
measure the concordance of individual patient pathways. Finally, we provide a rigorous survival
analysis to demonstrate the association of our concordance metric with survival, using a cohort of
stage III colon cancer patients. Although we focus on colon cancer specifically in this paper, our
inverse optimization-based approach is generalizable to other patient cohorts and even beyond the
healthcare context to general process management applications for which data-driven concordance
measurement is a critical need.
Our main contributions in this paper are as follows:
1. We propose the first inverse optimization-based approach for measuring pathway concordance
in any problem context. Methodologically, our approach differs from previous inverse optimization
models with the inclusion of a mixture of both “good” and “bad” data points; that is, points that the
optimal cost vector should fit well and points that it should not fit well, respectively. Our approach
also considers the novel setup where there is a primary (reference pathways) and secondary (patient
pathways) dataset, which should be given differential consideration when imputing the cost vector.
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2. We develop two metrics for goodness-of-fit assessment. The first metric extends a previously
developed metric for in-sample goodness-of-fit measurement between the decision model, the input
data, and the imputed parameters. This metric is tailored to our particular inverse optimiza-
tion model and considers the lower dimensionality of the feasible region in standard form linear
optimization problems such as network flow problems. The second metric, used for out-of-sample
measurement, uses the inversely optimized cost vector to calculate a concordance score for a given
flow vector (patient pathway). Both metrics are simple to compute and easily interpretable, with
intuitive mathematical properties such as taking values between 0 and 1, with 1 representing perfect
fit or concordance.
3. We provide an in-depth case study applying our inverse optimization-based models and met-
rics to real patient data from a cohort of stage III colon cancer patients. We show through a rigorous
survival analysis that there is a statistically significant association between the concordance score of
patient-traversed pathways and survival, validating the meaningfulness of our concordance metric.
We further quantify the value of our data-driven approach by demonstrating that the patient data-
driven concordance metric is much more strongly associated with survival than a metric developed
using only reference pathways and without access to the patient data.
All proofs are included in the Appendix.
2. Motivating a Graph-Based Inverse Optimization Approach
In this paper, we leverage network optimization and the corresponding graph-based representation
of the problem to measure pathway concordance. To motivate our approach, we briefly highlight
the differences between edit distance-based methods (Navarro 2001) and our proposed approach.
In particular, we show that our approach provides more granularity and modeling flexibility in
capturing different types of discordance, and provides a framework that facilitates data-driven
estimation of weights.
First, consider unweighted edit distance algorithms, which measure distance as the minimum
number of distortions or edits required to transform a source pattern into a target pattern (van de
Klundert et al. 2010, Forestier et al. 2012, Yan et al. 2018, Riesen 2015). The edit operations are
defined on the activities in the pathway and usually include insertions, deletions, substitutions,
and transpositions, although some algorithms may count a transposition as two substitutions. In
contrast, our graph-based approach measures distance using the difference in the total cost along
the arcs traversed by the two pathways. Note that edit distance has been extended to graph
structures where the edit operations are applied to nodes and arcs (Gao et al. 2010). In the context
of clinical pathways, the entire graph is simply a path representing the clinical events of interest
sequentially in time. A key difference is that graph edit distance compares two pathways represented
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as two distinct graphs, whereas in our approach the two pathways are distinct walks in a single,
pre-defined graph.
Our approach improves on edit distance algorithms by better characterizing pathway deviations
and optimally estimating weights for those deviations. We refer to arcs that are in a reference
pathway as “concordant” if they connect the desired activities in the order indicated according to
clinical guidelines. In contrast, “discordant” arcs are those that do not connect activities contained
in the reference pathways, or connect such activities out of sequence. The concordance of an
observed pathway is then a function of the discordant arcs present and the concordant arcs absent.
To illustrate the ability of our algorithm to better characterize pathway variation, we present
concrete examples shown in Table 1. Consider a network with an artificial start node S and end
node E that bookend all pathways and let A − B − C be a reference pathway represented by
the sequence of arcs (S,A), (A,B), (B,C) and (C,E). Now consider five example pathways listed
in Table 1, all of which have the same edit distance of one from A − B − C. We can see that
despite having the same edit distance, these pathways have different numbers of concordant and
discordant arcs. Concordance measurement based on absence of concordant arcs and presence of
discordant arcs implies that each pathway can have a different graph-based distance from the
reference pathway. Furthermore, when considering pathways with an edit distance of two or more
from the reference pathway, differences with graph-based distance measurement are magnified.
For example, two adjacent deletions are different from two nonadjacent deletions in terms of the
number of concordant and discordant arcs.
The preceding discussion assumes that all arcs and operations (in the edit distance setting)
are unweighted. If we now consider a weighted distance metric, an issue arises where the cost
of edits would need to be determined a priori and exogenously from our reference pathways. In
weighted edit distance, weights or costs are associated with each type of operation. The distance
between pathways then becomes the minimum cost of edit operations required to transform one
into the other. Determining the costs of each operation based on a set of reference and non-reference
pathways is complicated by the dependency of the edits on the costs. Expectation maximization
can be used, but this approach does not guarantee convergence to a global optimum (Neuhaus
and Bunke 2004, Ristad and Yianilos 1998). In contrast, our inverse optimization approach avoids
this dependency and can determine optimal costs for each arc by assuming pathways are optimal
solutions to an appropriately formulated optimization problem. The ability to optimally infer arc
costs or weights, together with finer characterization of pathway variation using concordant and
discordant arcs, are the main strengths of our inverse optimization approach.
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Table 1 Comparing concordant and discordant arcs in pathways that have edit distance of one from the
reference pathway
Pathway
Edit
operation
Missing
concordant
arcs
Extra
discordant
arcs
Pathway representation
A-B-C - 0 0
A-A-B-C
Insertion
(duplicated
activity)
0 1
X-A-B-C
Insertion
(discordant
activity)
1 2
B-C Deletion 2 1
X-B-C Substitution 2 2
B-A-C Transposition 3 3
Notes. Missing concordant arcs are dashed. Extra discordant arcs are red.
3. Inverse Optimization for Pathway Concordance Measurement
In this section, we first present a model of the clinical activity network representing all the activities
that a cancer patient can undertake during his or her cancer care journey. A patient journey is
modeled as a walk through the network. We assume that each arc incurs a cost when a patient
takes that arc and that the reference pathways are optimal solutions with respect to an appropriate
optimization problem defined on this network. Our goal is to find the costs on each arc and to use
it to measure the concordance of a given pathway to the reference pathways.
3.1. The Clinical Activity Network
Let N be a set of m nodes and let A⊆N ×N be a set of n directed arcs in the network. Nodes
represent clinical activities that can be undertaken by a patient. To model the cost of undertaking
a specific activity i, we split each activity node into two nodes, is and ie, representing the start
and end, respectively, of activity i, and then add an arc (is, ie) with cost cisie . The remaining
arcs connect the end node of some activity i with the start node of another activity j. Each arc
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(ie, js) has an associated cost ciejs , representing the cost of undertaking activity j immediately
after activity i. The set A also includes arcs of the form (ie, is), which allows the network to model
a patient journey that involves consecutive repetitions of activity i. Finally, we add two artificial
nodes representing the common start and end of each patient journey. Thus, m is equal to two
times the number of clinical activities plus two.
A reference pathway is represented as the solution of a shortest path problem on this network. We
write this shortest path problem as a standard form linear optimization problem representing the
corresponding network flow model: min
x
{c′x : Ax = b,x≥ 0}. We denote this model the “forward”
model and will refer to it as FO(c). The decision vector x∈Rn describes the flow on each arc. The
matrix A∈R(m−1)×n is the node-arc incidence matrix, but without the mth row, which corresponds
to the flow balance constraint of the artificial end node. Thus, it is full rank. The parameter
b∈Rm−1 is a vector of zeros except with a +1 at the artificial start node.
A patient journey will be represented as a walk on this network. Note that it may not necessarily
be a path since patients may visit an activity or traverse an arc several times. Thus, a patient
journey through the network can still be represented by a flow vector x ∈ Rn, except that the
value of xij may be greater than one, representing the number of times arc (i, j) is traversed in the
corresponding walk. In keeping with the medical terminology, we will refer to a patient journey as
a patient “pathway”, which in general should be thought of as a walk through the network. We
will reserve the use of the phrase “path” for the mathematical concept of a walk without repeated
nodes.
Note that with the current setup, costs are “path-independent”. That is, the cost of traversing
arc (i, j) is equal to cij regardless of how the walk arrives at node i. To model path-dependent
costs, where the cost of completing activity j immediately following activity i depends on what
activities were completed prior to i, we could modify the nodes in the network from representing
a single activity to representing the sequence of activities from the artificial start node to the
current activity. That is, imagine a network organized in “layers”, where the first layer of nodes
comprises all activities that can be reached from the start node in one step, the second layer of nodes
comprises all sequences of activities that can be reached in two steps, etc. While the cost-dependent
approach provides richer modeling possibilities, the downside is an exponential explosion in the
number of nodes in the network. Thus, we proceed with the network as currently defined (i.e., with
path-independent costs) to maintain a parsimonious model, and instead integrate path-dependent
behavior into the constraints of the inverse optimization model, which is described next.
3.2. Inverse Optimization Model
Our goal is to identify a cost vector c ∈ Rn that minimizes the aggregate suboptimality of given
reference pathways, assuming they represent shortest paths. We first present a basic inverse opti-
mization model that provides an exact formulation of this problem. Then, we introduce a second
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formulation that uses patient pathways to refine the optimal cost vector returned by the first model,
in order to improve the association between pathway concordance and survival.
3.2.1. A Model Using Only Reference Pathways. Let Xˆ r = {xˆr1, . . . , xˆrR} denote the set
of R reference pathways, each assumed to be feasible flow vectors for the forward problem. We
follow a standard approach to formulating the inverse optimization problem using duality of linear
optimization. Let p ∈ Rm−1 be the dual vector associated with flow balance constraints. The fol-
lowing formulation is an inverse optimization model that minimizes the sum of squared absolute
duality gaps induced by the cost vector c and the R reference pathways:
IOref(Xˆ r) : minimize
c,p,r
R∑
q=1
(rq)
2
subject to A′p≤ c,
c′xˆrq = b
′p + rq, q= 1, . . . ,R,
‖c‖∞ = 1,
Ac = 0.
(1)
The first constraint represents dual feasibility. The second constraint defines the duality gap
rq for each reference pathway xˆ
r
q as the difference between the primal and dual objective values.
Each duality gap variable is nonnegative since the reference pathways are feasible for the forward
problem. The third constraint is a normalization constraint to ensure the cost vector is not trivial
(i.e., non-zero). The fourth constraint is needed to ensure that c lies in the lower dimensional
space defined by the constraints Ax = b. Since c lies in the space defined by the intersection of
the equality constraints (a′ix = bi, i= 1, . . . ,m− 1), it must be orthogonal to the vectors defining
those constraints (ai). Without the constraint Ac = 0, an optimal solution (i.e., cost vector) to
formulation (1) could be orthogonal to the entire forward feasible region, which would render c
uninformative since every feasible flow vector would be optimal. To our knowledge, the issue of
finding an optimal cost vector via inverse optimization for a lower dimensional feasible region
(which is characteristic of any inverse network flow problem) has not been studied in the inverse
optimization literature previously. Note that the constraint Ac = 0 means that the optimal cost
vector will be a circulation.
To model additional application-specific considerations, such as user-specified rankings between
certain activities or preferences for how a patient should begin or end her pathway, we will add a
set of constraints on the cost vector, c∈ C, to formulation (1). Specific examples of such constraints
are provided in Section 5.
First, we prove that formulation (1) has an optimal solution for any non-trivial network.
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Lemma 1. IOref(Xˆ r) has an optimal solution if and only if there are at least two distinct paths
from the start node to the end node.
Given Lemma 1, we assume going forward that the network is non-trivial (i.e., more than a single
path) and IOref(Xˆ r) always has an optimal solution. Next, we present an important property of
an optimal solution to IOref(Xˆ r).
Proposition 1. Let (c∗,p∗,r∗) be an optimal solution to formulation (1). Then, the network
with arc costs c∗ does not contain any directed negative cost cycles.
This result has an intuitive real-world interpretation. It says that a patient traversing the cancer
care network cannot accrue a positive benefit through repeating any sequence of activities. This
will certainly be the case if the outcome is measured in terms of monetary cost of the activities.
But even viewed through the lens of survival, it makes sense that such negative cost cycles do not
exist. Otherwise, there would be a sequence of activities that guarantees improved survival, which
is not realistic. We also note that a finite optimal value for (1) is important for the goodness-of-fit
and concordance metrics, which we define later.
Formulation (1) is non-convex because of the normalization constraint. However, it can be solved
using polyhedral decomposition: solving 2n quadratic optimization problems where the normaliza-
tion constraint is replaced with cij ∈ [−1,1] for all (i, j)∈A and with one additional constraint on
one cij being set to either +1 or −1:
IOrefij (Xˆ r) : minimize
c,p,r
R∑
q=1
(rq)
2
subject to A′p≤ c,
c′xˆrq = b
′p + rq, q= 1, . . . ,R,
cij =−1∨ cij = 1,
− 1≤ cij ≤ 1, (i, j)∈A,
Ac = 0.
(2)
Furthermore, if in a particular problem context it is clear which arc should be either the most
heavily rewarded (set cij = −1) or heavily penalized (set cij = +1), then only one of these 2n
problems needs to be solved. As we demonstrate later, this is the case for our clinical problem.
3.2.2. Refining the Solution using Patient Data. Let Xˆ s = {xˆs1, . . . , xˆsS} denote a dataset
of S patient pathways with good clinical outcomes (i.e., survived) and Xˆ d = {xˆd1, . . . , xˆdD} denote a
dataset of D patient pathways with poor clinical outcomes (i.e., died), all assumed to be feasible
flow vectors for the forward problem. If formulation (1) has multiple optimal solutions, we can
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use these two datasets to determine a cost vector that not only maximizes fit with the reference
pathways, but also provides “separation” between Xˆ s and Xˆ d. Once formulation (1) is solved and
an optimal duality gap vector, r∗, is generated, we use r∗ as input into the following inverse
optimization model:
IOpat(Xˆ s, Xˆ d,r∗) : minimize
c,p,s,d
D
S
S∑
q=1
sq −
D∑
q=1
dq
subject to A′p≤ c,
c′xˆrq = b
′p + r∗q , q= 1, . . . ,R,
c′xˆsq = b
′p + sq, q= 1, . . . , S,
c′xˆdq = b
′p + dq , q= 1, . . . ,D,
‖c‖∞ = 1,
Ac = 0.
(3)
Since data from Xˆ s represents “good” data, we treat it like input to traditional inverse opti-
mization models (and like the reference pathways), where the goal is to minimize the aggregate
suboptimality of these data points. However, since Xˆ d consists of “bad” data points, we do not
want to learn a cost vector that fits this data well. Instead, the cost vector should generate data
points as far away as possible from those in Xˆ d when solving the forward problem, which is why
in formulation (3) the objective maximizes suboptimality with respect to Xˆ d. The weight D/S
simply scales the two sub-objectives to account for the difference in the number of data points in
the two groups. The second constraint forces the cost vector to achieve the optimal duality gap
found in model (1). In other words, all feasible solutions of (3) are optimal solutions to (1). The
third and fourth constraints define the duality gaps with respect to the pathways in Xˆ s and Xˆ d,
respectively. Again, the duality gaps are nonnegative since all patient pathways are feasible for the
forward problem. The remaining constraints are as defined in (1). Formulation (3) can be solved
using the same polyhedral decomposition technique described previously. The difference is that
each subproblem is a linear optimization problem, since the objective function is now linear. A
linear objective was chosen for formulation (3) to facilitate the combination of duality gaps that
needed to be minimized and maximized in the same objective.
Next, we establish that formulation (3) will always return an optimal cost vector.
Proposition 2. IOpat(Xˆ s, Xˆ d,r∗) has an optimal solution.
In our numerical results, we implement two slightly different versions of formulation (3). In
Section 6, we visualize the solution of our inverse optimization model (i.e., the cost vector) and
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compute goodness-of-fit using all of our patient data to form the sets Xˆ s and Xˆ d. These results
are thus “in-sample”. However, the patient concordance scores in that section and in the survival
analysis in Section 7 are computed “out-of-sample”. That is, we use only a subset of the full patient
dataset to form Xˆ s and Xˆ d in model (3), and the resulting optimal cost vector c∗ is used to calculate
a concordance score for the patients that were not used to determine c∗. These out-of-sample
concordance scores then constitute an independent variable in the survival analysis model.
4. Goodness-of-Fit and Concordance Metrics
In this section, we develop two fitness metrics. The first measures the goodness of fit of the optimal
cost vector generated by the inverse optimization model against the input data. The second metric
measures the concordance of a given patient pathway against the reference pathways, using the
optimal cost vector generated by the inverse optimization model. It should be applied to patient
pathways that have yet to be observed and that are not in the “training data” that was used to
generate optimal cost vector.
4.1. Goodness-of-Fit of the Cost Vector
We extend a previously developed goodness-of-fit metric for inverse optimization, the coefficient
of complementarity (Chan et al. 2019), so that it is appropriate for measuring the fitness of cost
vectors produced by model (3). The previous metric required the forward feasible region to be
full-dimensional, which is not the case here due to the flow balance equality constraints. Our metric
is like R2 in linear regression in that it measures the fit between the input data and the estimated
model, and possesses analogous mathematical properties. First, we present a general form of our
goodness-of-fit metric that is applicable to any problem, regardless of whether the forward feasible
region is full-dimensional, and examine its theoretical properties. Then, we introduce a modified
form that is appropriately tailored to the lower-dimensional space in which the forward feasible
region resides.
Since our primary goal is to find a cost vector that fits the reference pathways, and since model (3)
simply searches among the optimal cost vectors for one that separates patients with good and bad
outcomes, we focus on measuring model-data fit with respect to the reference pathways and not
the patient data.
Let c∗ be an optimal cost vector for (3) and c1, . . . ,cT be a set of cost vectors that are feasible
for (1). Let x∗ be an optimal solution to FO(c∗) and x1, . . . ,xT be defined similarly with respect
to c1, . . . ,cT . We define the goodness of fit of c
∗ with respect to the reference pathways Xˆ r as
ρ(Xˆ r) = 1−
∑R
q=1
(
c∗′xˆrq − c∗′x∗
)2
1
T
∑T
t=1
(∑R
q=1
(
c′txˆrq − c′txt
)2) . (4)
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Note that c∗′x∗ and b′p∗ can be used interchangeably since they represent the optimal primal and
dual objective values, respectively, which are equal. Therefore, c∗′xˆrq − c∗′x∗ = r∗q . Similarly, each
term c′txˆ
r
q−c′txt in the denominator is equal to a duality gap for a reference pathway q with respect
to the cost vector ct.
Next, we show that ρ(Xˆ r) has attractive mathematical properties that facilitate its use and
interpretation. Recall that an optimal c∗ for formulation (3) is also optimal for (1). Thus, although
Theorem 1 focuses on formulation (1), it is equally applicable to cost vectors generated from
model (3). Some additional notation is needed before proceeding. Let A(k) ⊂A be a set of k arcs
from the network, k= 1, . . . , n− 1. We define
ρ(k)(Xˆ r) = 1−
∑R
q=1
(
c∗′(k)xˆrq − c∗′(k)x∗
)2
1
T
∑T
t=1
(∑R
q=1
(
c′txˆrq − c′txt
)2) ,
where c∗(k) is an optimal solution for IO
ref
(k)(Xˆ r), defined as IOref(Xˆ r) with additional constraints
cij = 0 for (i, j) /∈A(k).
Theorem 1. 1. Optimality: ρ(Xˆ r) is maximized by an optimal solution to IOref(Xˆ r).
2. Boundedness: ρ(Xˆ r)∈ [0,1].
3. Monotonicity: ρ(k)(Xˆ r)≤ ρ(k+1)(Xˆ r) if A(k) ⊂A(k+1).
Given the reference pathways Xˆ r and an optimal solution c∗ to (1) (or (3)), ρ(Xˆ r) measures
the degree to which the reference pathways are shortest paths with respect to c∗. If all reference
pathways are shortest paths with respect to c∗, then ρ(Xˆ r) = 1.
When the forward feasible region is full-dimensional, an appropriate choice for the baseline cost
vectors consist of the vectors normal to the constraints defining the feasible region, i.e., the rows of
the coefficient matrix A (Chan et al. 2019). Thus, where it is straightforward to work directly in
the lower-dimensional space, we should modify the computation of ρ(Xˆ r) to avoid having to make a
subjective choice for c1, . . . ,cT . In particular, we can eliminate the equality constraints Ax = b by
variable substitution (details in Appendix B) and compute the following “full-dimensional” version
of ρ(Xˆ r) in dimension n− (m− 1)
ρf (Zˆr) = 1−
∑R
q=1
(
c∗′xˆrq − c∗′x∗
)2
1
n
∑n
t=1
(∑R
q=1
(
h′tzˆrq − bt
)2) , (5)
where Zˆr = {zˆr1, . . . , zˆrR} and ht defines the t-th inequality constraint defining the feasible region
in the lower-dimensional space (i.e., h′tz≥ bt, t= 1, . . . , n). Importantly, the properties proved in
Theorem 1 hold for ρf (Zˆr) (Chan et al. 2019). In our numerical results, we project the reference
pathways and forward feasible region to the lower-dimensional space and calculate ρf (Zˆr) when
measuring fitness between the optimal cost vector and the reference pathways.
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4.2. Concordance of a Patient Pathway
Using the cost vector generated by inverse optimization, our concordance metric ω(xˆ) measures
the cost of a patient pathway xˆ against the cost of a shortest path with respect to c∗ as
ω(xˆ) = 1− c
∗′xˆ− c∗′x∗
M(xˆ)− c∗′x∗ (6)
where M(xˆ) = max
x
{c∗′x : Ax = b,x ≥ 0,‖x‖1 ≤ ‖xˆ‖1,x is a walk}. In other words, M(xˆ) is the
cost of a longest walk, which can be determined via dynamic programming (see Appendix C).
Note that we use the cost of the shortest path, c∗′x∗, instead of the cost of a reference pathway
when measuring concordance. Since a reference pathway may not actually be a shortest path under
c∗, and since there may be multiple reference pathways with different costs under c∗, we define
the concordance metric using c∗′x∗ to have a consistent and objective baseline. Of course, if the
inverse optimization model finds a cost vector that perfectly fits all of the reference pathways (i.e.,
ρ= 1), then the cost of all reference pathways will be equal to c∗′x∗, and ω(xˆ) will be measuring
concordance directly against the cost of the reference pathways.
Next, we show that ω(xˆ) has the attractive property of being a unitless metric between 0 and
1, with 1 representing a perfectly concordant pathway (i.e., xˆ is a shortest path with respect to
c∗) and 0 representing a perfectly discordant pathway (i.e., xˆ is a longest walk with respect to c∗
among all walks of at most the same number of steps as xˆ).
Theorem 2. Given any feasible solution xˆ to the forward problem:
1. ω(xˆ)∈ [0,1],
2. ω(xˆ) = 1 if and only if c∗′xˆ = c∗′x∗,
3. ω(xˆ) = 0 if and only if xˆ∈ arg max
x
{c∗′x : Ax = b,x≥ 0,‖x‖1 ≤ ‖xˆ‖1,x is a walk}.
We end this section with a brief discussion on M(xˆ). The denominator of ω(xˆ) normalizes the
cost difference between the given pathway and an ideal pathway using the cost of the longest walk
with length up to the length of xˆ. Normalizing in this fashion implies that a longer walk could
be, paradoxically, more concordant than a shorter walk, something that would not occur if the
normalization term was a constant. However, we choose to normalize usingM(xˆ) for several reasons.
First, this normalization allows the computation of ω(xˆ) to depend only on the given pathway xˆ
(and c∗) and not any other pathways. Normalizing by a fixed amount, M , while maintaining the
property that ω(xˆ)≥ 0 for all xˆ would require that M be longer than all patient pathways that
would be considered by ω(xˆ), an amount that could not be known a priori. Second, this approach
aligns with common normalization approaches for edit distance metrics that are based on string
length (Yujian and Bo 2007). Later, in our numerical results, we show that using M(xˆ) results in
an approximately normal distribution of ω(xˆ) for our dataset.
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5. Application to Stage III Colon Cancer
In this section, we demonstrate the application of our inverse optimization framework to measure
clinical pathway concordance, focusing on stage III colon cancer.
5.1. Problem Background
5.1.1. Disease Pathway Management at Cancer Care Ontario. The Disease Pathway
Management (DPM) program at Cancer Care Ontario takes a systems view of setting priorities
for cancer control, planning cancer services and improving the quality of cancer care in Ontario.
DPM views patient journeys across the entire cancer continuum as part of an integrated process,
as opposed to evaluating individual points of care in isolation. Clinicians are engaged to establish
evidence-based best practices for the sequence of activities patients should take through the care
network. These best practices are captured in pathway maps (Cancer Care Ontario 2019b), which
reflect clinical guidelines for the care that patients should receive to optimize clinical outcomes.
Pathway maps cover points of care spanning disease prevention, screening, diagnosis, treatment,
recovery and end-of-life palliative care.
5.1.2. Stage III Colon Cancer and Pathway Map. Colon cancer is a malignant tumor of
the colon. In 2018, roughly 180,000 people were diagnosed with colorectal cancer in North America
and there were 64,000 deaths due to this cancer (World Health Organization 2019); colon cancer
constitutes approximately 70% of the colorectal cancer cases (Colorectal Cancer Alliance 2019).
Stage III colon cancer is characterized by metastasis of the cancer to the lymph nodes near the
colon or by direct invasion into nearby organs. Chemotherapy is recommended as adjuvant therapy
for surgically resected stage III disease. Twelve cycles of chemotherapy constitutes a complete
treatment course.
The stage III colon cancer pathway map (Cancer Care Ontario 2019a) spans diagnosis and
treatment, and contains the following major categories of activities: 1) clinical consultations, 2)
endoscopy, 3) diagnostic imaging, 4) surgery, 5) adjuvant chemotherapy. Clinical consultations
include consultations with a gastroenterologist (GI), surgeon and medical oncologist (MO). Diag-
nostic imaging includes imaging of the abdomen, pelvis and chest with any of the following modal-
ities: computed tomography (CT), magnetic resonance imaging (MRI), ultrasound (US), or x-ray.
All concordant pathways must start with an endoscopy followed by abdominal imaging, chest
imaging, surgical resection of the tumor, a MO consultation and finally chemotherapy. The patient
will have had a GI or surgical consultation prior to the endoscopy, and a surgical consulta-
tion at some point before the surgical resection. Similarly, a MO consultation must occur before
chemotherapy, preferably after the surgical resection. Abdominal imaging may take place as either
an abdomen CT scan followed by a pelvis CT scan, or as an abdominal ultrasound. Similarly, chest
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CT scans or chest x-rays constitute chest imaging. Chemotherapy is considered concordant if the
patient pathway includes the recommended 12 treatment cycles. All of these different combinations
are captured in the pathway map. Enumerating all of the possible concordant pathways from the
pathway map results in 108 distinct reference pathways for stage III colon cancer.
5.2. Data
5.2.1. Data Sources. In Ontario, health care encounters are recorded in administrative
databases using standardized methods. Using encrypted person-specific identifiers, we linked multi-
ple sources to select the study population, define patient characteristics, and record activity related
to screening, imaging, treatments, emergency department (ED) visits, and death. The data sources
used in this study are listed in Appendix D.
5.2.2. Study Population. We developed a population-based cohort of individuals newly diag-
nosed with stage III colon cancer in 2010 in Ontario. Their clinical activities were recorded from
six months prior to cancer diagnosis until either death or censoring at four years following diagno-
sis. Included patients had surgical resection within one year of diagnosis. Patients were excluded
based on the following exclusion criteria: no Ontario health insurance number, residence outside
of Ontario, non-incidental cancer diagnosis, any prior history of cancer or identification of a new
primary cancer during the follow-up period, cancers diagnosed based on death records, unknown
cancer stage, and unknown tumor histology. The final cohort contained 763 patients, 257 of whom
died (from any cause) within the four-year post-diagnosis observation period.
The dataset is an event-log for each patient in the cohort describing the activities undertaken and
their corresponding times relative to the date of diagnosis. However, not all events in the event-log
are relevant to the diagnostic and treatment phases of care, which is our focus. Therefore we refine
each patient’s event-log by filtering out events earlier than 30 days prior to diagnosis and following
one year post-diagnosis, since patients are expected to complete diagnostic and treatment activities
within one year. If the patient completed chemotherapy (all 12 cycles) within the year, we remove
all events after their last chemotherapy cycle. We also remove activities that have no bearing
on concordance. For example, minor procedures like fecal occult blood tests and barium enemas
were deemed inconsequential or extremely infrequent and were removed. All data refinements were
implemented following consultations with clinicians.
5.3. Network Design
Next, we form a directed graph representing the clinical activity network based on activities from
the pathway map, observed patient pathways, and discussions with clinical experts from the DPM
team.
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In clinical practice, GI, surgery and MO consultations always precede endoscopies, surgical
resection and chemotherapy treatment, respectively. We therefore do not include nodes for these
consultations in the graph and assume that they occur with the corresponding procedure. However,
it is possible for patients to have additional consultations, which are costly for the system and
deemed discordant. These discordant consultations, like visits to the emergency department, were
quite prevalent in our dataset, so we included EXTRA CONSULT and ED VISIT as nodes in the
graph. Another reason to include the latter is because reducing unnecessary visits to the ED is a
Cancer Care Ontario priority.
Imaging events are distinct from consultations in that they are not implicit with other events, so
we keep them as separate standalone activities. Imaging activities that were deemed functionally
equivalent from a concordance perspective were merged into a single node. For example, abdomen
MRI and ultrasound were combined into the node ABDOMEN MRI/US. We formed a single node
for PELVIS MRI/US and CHEST IMAGING (which encompasses chest X-rays and CT scans) for
the same reason. CT is preferred over the other imaging modalities for abdomen and pelvis, so we
defined separate nodes for abdomen CT and pelvis CT.
Finally, our discussions with experts revealed that the type of treatment received by the patient
should have extra bearing on their concordance score. To model the different possible ways each
clinical or patient pathway can end, we include an “outcome layer” with four distinct nodes. Each
pathway must exit the graph via one of these four nodes. Patients who receive 12 chemotherapy
treatments exit through the node CHEMO COMPLETE. Receiving between 1 and 11 chemother-
apy treatment cycles leads to an exit through the node CHEMO PARTIAL. The remaining path-
ways (no chemotherapy) exit either through the nodes MO CONSULT END (if the patient receives
an MO consultation) or RESECTION END (if the patient does not). Recall that our patient cohort
only includes patients who had surgical resection. The final network design used in our model is
shown in Figure 1.
5.4. Inverse Optimization Model Specification
Since our final network design merged together several activities specified in the Cancer Care
Ontario pathway map, the set of 108 reference pathways were reduced to two distinct reference
pathways. One reference pathway is shown in Figure 1. The other reference pathway replaces
ABDOMEN CT and PELVIS CT with ABDOMEN MRI/US. The network, reference pathways,
survived patient pathways and died patient pathways constitute the (A,b), Xˆ r := {xˆr1, xˆr2}, Xˆ s and
Xˆ d, respectively, in formulations (1) and (3). The value of the (i, j)-th component of xˆrq is 1 if
reference pathway q includes arc (i, j) and 0 otherwise. Patient pathways are mapped to the graph
similarly, except that each component of the vector represents the number of times that arc is
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Figure 1 Stage III colon cancer clinical activity network with a reference pathway highlighted
traversed (which may be greater than one) in the patient pathway. Finally, with respect to C, we
included three sets of context-specific constraints on the imputed cost vector: 1) activity ranking
constraints, 2) subpath constraints, and 3) penalty constraints.
Activity ranking constraints enforce a relative importance between pairs of activities. For exam-
ple, clinical experts deemed ABDOMEN CT to be a more important activity than PELVIS CT.
To account for this relationship in the model, we introduced a constraint that enforced the cost
of completing ABDOMEN CT to be at most the cost of completing PELVIS CT (since it is a
minimization problem). Specifically, if i represents ABDOMEN CT and j represents PELVIS CT,
then the constraint would be cisie ≤ cjsje . There were eight such constraints in total between the
nine non-outcome layer nodes.
Subpath rankings generalize activity ranking constraints to a sequence of nodes. For example, the
subpath of ENDOSCOPY to ABDOMEN CT to PELVIS CT to CHEST IMAGING was preferred
to the subpath of ENDOSCOPY to ABDOMEN MRI/US to CHEST IMAGING. Therefore, the
sum of the arc costs along the first subpath (starting from the end node of ENDOSCOPY and
ending with the start node of CHEST IMAGING) was constrained to be at most the sum of the arc
costs along the second subpath. There were four such constraints in total. The first is the subpath
ranking above. The remaining three rank the subpaths exiting the graph through the four outcome
layer nodes, starting each subpath at RESECTION. In particular, the nodes in the outcome layer
as depicted in Figure 1 are arranged from top to bottom in order of most preferred to least preferred
outcome. For example, if i represents RESECTION, j represents RESECTION END, k represents
MO CONSULT END, and E represents the final end node, then the subpath ranking between
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RESECTION END and MO CONSULT END would be ciejs + cjsje + cjeE ≥ cieks + ckske + ckeE.
Similar subpath rankings were generated for MO CONSULT END versus CHEMO PARTIAL and
CHEMO PARTIAL versus CHEMO COMPLETE.
Finally, since CHEMO COMPLETE is the best outcome node through which to exit the graph,
we set the cost of the CHEMO COMPLETE to END arc to −1, anchoring all the arc costs relative
to this one. This constraint is also beneficial from a model tractability perspective. Recall that
the inverse optimization model is solved via polyhedral decomposition, which amounts to solving
several distinct optimization problems, each with a constraint of the form cij = 1 or cij =−1. Since
we have an application-specific justification for setting one of the arc costs so that the constraint
‖c‖∞ = 1 is automatically satisfied, we only need to solve a single optimization problem.
6. Inverse Optimization Results
We obtained an optimal cost vector, c∗, by first solving formulation (1) followed by formulation (3)
with the inputs described in Section 5.4. This cost vector comprises all arc costs and by definition
minimizes the total suboptimality error of the two reference pathways, xˆr1 and xˆ
r
2, and secondar-
ily minimizes (maximizes) the suboptimality error of the patient pathways from survived (died)
patients in Xˆ s (Xˆ d). Figure 2 illustrates the c∗ values on the graph. Recall that since c∗ satisfies
Ac∗ = 0, the sum of the costs on the incoming and outgoing arcs for each node are equal. As a
consequence, the associated cost of passing through each node in the outcome layer is doubled,
since each node in that layer has only one outgoing arc (i.e., the intra-activity arc (is, ie) followed
by the arc from the outcome node ie to END).
Given the optimal cost vector c∗, we found that ρf (Zˆr) = 1. In other words, the duality gap
associated with the two reference pathways was zero, indicating perfect model-data fit with the
reference pathways. However, the average error from the patient pathways was positive, indicating
that they are not shortest paths in general.
Finally, we calculated the concordance score of each patient pathway using (6) following a 10-fold
cross-validation approach. The patient data was randomly partitioned into ten subsets (“folds”)
that maintained the same class balance as the entire dataset. For each fold, the inverse optimization
model was trained using the two reference pathways and 90% (nine of the subsets) of the patient
data. The resulting cost vector was used in ω(xˆ) to measure the concordance of patient pathways in
the out-of-sample 10% (the remaining subset). This process was carried out for all 10 folds and the
distribution of out-of-sample concordance scores for the entire patient cohort is shown in Figure 3.
The fact that this distribution is approximately normal stems from the choice of normalization in
ω(xˆ). As Figure 4 shows, the distributions of the duality gap  and pathway length ‖xˆ‖1 are both
skewed similarly, resulting in an approximately linear relationship between the two quantities. In
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Figure 2 Stage III colon cancer clinical activity network with optimal cost vector overlaid
Figure 3 Distribution of concordance score over patient cohort
other words, the lack of fitness of a given patient pathway is associated with its corresponding
length, and dividing one by the other creates the shape of the distribution seen in Figure 3.
As a crude analysis of association between concordance and survival, we generated smoothed
cumulative distributions of the concordance scores, stratified by survival outcome, in Figure 5.
Interestingly, the figure depicts first-order stochastic dominance, with a clear separation between
patients who survived versus those who died. That is, for any given concordance score ω0 ∈ [0,1],
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Figure 4 Relationship between duality gap and pathway length
the probability of scoring below ω0 is higher for patients who died. Note that stochastic dominance
is used in medical decision making to compare the costs or effectiveness of two or more distinct
treatments (Leshno and Levy 2004, Sendi et al. 2003).
The results shown in Figure 5, while intuitive, do not provide a rigorous measure of the relation-
ship between concordance and survival. Thus, in the next section, we perform a detailed survival
analysis to establish the association between pathway concordance and survival.
7. Validating the Concordance Metric against Survival
7.1. Methods
For each patient in our study population, we obtained their characteristics as outlined in Section 5.2.
Patient characteristics were summarized as counts with proportions for categorical data and means
with standard deviations for continuous data. We binned the patient concordance scores into terciles
and difference in covariate distributions among concordance score terciles was assessed with a chi-
squared test for categorical variables and a one-way ANOVA for means and standard deviations.
A Kaplan-Meier estimator was used for graphical presentation of (unadjusted) survival over time
by the terciles of concordance scores. Difference in survival probabilities was assessed using the
log-rank test statistic.
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Figure 5 Cumulative distribution of concordance score over entire cohort stratified by patient outcome
A semi-parametric Cox proportional hazards model was implemented to evaluate the associa-
tion between concordance scores and mortality (Cox 1971). Cox regression provides estimates of
association between each variable and the hazard of event, i.e., the instantaneous rate of event. A
unit increase in a covariate is multiplicative with respect to the hazard. An estimate of the hazard
ratio (HR) above 1 indicates a variable that is positively associated with the risk of mortality, i.e.,
negatively associated with survival.
A range of known potential confounders and predictors of survival was assessed for inclusion
in the model. These variables consist of demographic characteristics (age, sex, rural residency,
quintiles of neighbourhood median income, terciles of immigrant population), Charlson comorbidity
score (Charlson et al. 1987, Quan et al. 2005), cancer diagnostic and treatment characteristics
(screening category, stage, tumor grade, emergent surgery status, length of hospital stay following
the surgical treatment), and healthcare utilization a year prior to diagnosis (number of outpatient
visits, presence of in-patient admissions, presence of ED visits), which is a proxy for overall patient
health. Screening category refers to frequency and timing of blood tests (James et al. 2018). Stage
specifies the cancer sub-stage, which denotes severity. The emergent surgery indicator refers to
patients who had an urgent in-hospital admission when the surgical resection was performed.
We employed preliminary variable selection to control for important confounding effects while
excluding covariates that would compromise model efficiency. Variable importance in predicting
mortality was evaluated using an ensemble tree method for analysis of right-censored survival data
(Ishwaran et al. 2008).
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For the selected model, assumption of a linear relationship between a continuous independent
variable and the outcome was evaluated by plotting the residuals against the covariate. If nonlin-
earity was detected either from the plots of Martingale residuals or Schoenfeld residuals, restricted
cubic splines were used to model the continuous predictor (Stone and Koo 1985).
Variance of the estimated association between the concordance score and survival can increase
in case of overfitting. Bootstrap model validation with 1000 resamples was performed to evaluate
the degree of overfitting and potential overadjustment for confounders (Harrell Jr 2015).
Patients were excluded from the final survival model if they did not have all required covariate
values, other than tumor grade, recorded. Patients who died within one year of diagnosis were also
excluded, as they did not have the opportunity to complete their treatment journey in accordance
with the clinical guidelines.
7.2. Results
A total of 665 individuals met the inclusion criteria for survival analysis. The mean age at diagnosis
was 67.8 years (standard deviation = 13.2). Of the included patients, 165 (24.8%) died, with a
higher proportion of deaths occurring among those with low concordance scores (38.5%, p-value
< 0.0001).
Table 2 lists the characteristics of the entire cohort and by concordance terciles. Significant
differences between the terciles were observed for age, rural residency, comorbidity score, health-
care utilization, cancer stage, and characteristics related to cancer treatment. Sex, neighbourhood
income and immigrant population, screening group, and tumor grade were not significantly different
across terciles.
Table 2: Characteristics of stage III colon cancer cohort
included in the survival analysis
Characteristic
Low
(n=221)
Medium
(n=222)
High
(n=222)
Total
(n=665)
p-value
Death, n (%) 85 (38.5) 49 (22.1) 31 (14.0) 165 (24.8) <0.0001
Concordance score, mean (SD) 0.4 (0.1) 0.5 (0.0) 0.7 (0.1) 0.5 (0.2) <0.0001
Patient characteristics
Age at diagnosis, mean (SD) 74.0 (10.7) 65.9 (13.6) 63.4 (12.8) 67.8 (13.2) <0.0001
Female, n (%) 121 (54.8) 119 (53.6) 101 (45.5) 341 (51.3) 0.1044
Rural residency, n (%) 39 (17.6) 22 (9.9) 25 (11.3) 86 (12.9) 0.0348
Neighbourhood Income Quintile, n (%)
1 (lowest) 47 (21.3) 60 (27.0) 37 (16.7) 144 (21.7) 0.4321
2 40 (18.1) 42 (18.9) 44 (19.8) 126 (18.9)
3 48 (21.7) 40 (18.0) 46 (20.7) 134 (20.2)
4 46 (20.8) 42 (18.9) 53 (23.9) 141 (21.2)
5 (highest) 40 (18.1) 38 (17.1) 42 (18.9) 120 (18.0)
Chan et al.: Inverse Optimization for Clinical Pathway Concordance
24
Neighbourhood Immigration Tercile, n (%)
1 (lowest) 147 (66.5) 133 (59.9) 140 (63.1) 420 (63.2) 0.2832
2 49 (22.2) 47 (21.2) 48 (21.6) 144 (21.7)
3 (highest) 25 (11.3) 42 (18.9) 34 (15.3) 101 (15.2)
Charlson score = 0, n (%) 193 (87.3) 208 (93.7) 215 (96.8) 616 (92.6) 0.0022
Number of ED Visits in the year
before cohort entry, mean (SD)
0.7 (1.4) 0.4 (1.1) 0.3 (0.7) 0.5 (1.1) 0.0051
Number of OHIP Outpatient Vis-
its in the year before cohort entry,
mean (SD)
27.5 (39.6) 17.7 (18.7) 14.5 (16.0) 19.9 (27.4) <0.0001
Cancer-related characteristics
Screening group, n (%)
None 118 (53.4) 120 (54.1) 109 (49.1) 347 (52.2) 0.5905
Repeated 12 (5.4) 16 (7.2) 12 (5.4) 40 (6.0)
Diagnostic 31 (14.0) 34 (15.3) 30 (13.5) 95 (14.3)
Sporadic 60 (27.1) 52 (23.4) 71 (32.0) 183 (27.5)
Stage at diagnosis, n (%)
IIIA (least advanced) 17 (7.7) 12 (5.4) 32 (14.4) 61 (9.2) 0.0191
IIIB 134 (60.6) 136 (61.3) 122 (55.0) 392 (58.9)
IIIC (most advanced) 70 (31.7) 74 (33.3) 68 (30.6) 212 (31.9)
Tumor Grade Category, n (%)
Low 173 (78.3) 172 (77.5) 182 (82.0) 527 (79.2) 0.6545
High 40 (18.1) 40 (18.0) 30 (13.5) 110 (16.5)
Unknown 8 (3.6) 10 (4.5) 10 (4.5) 28 (4.2)
Emergent surgery, n (%) 110 (49.8) 65 (29.3) 19 (8.6) 194 (29.2) <0.0001
Length of in-hospital stay post
surgery, mean (SD)
13.6 (17.0) 6.9 (4.7) 5.4 (2.1) 8.6 (10.8) <0.0001
ED visits in the first year post diag-
nosis, n (%)
192 (86.9) 182 (82.0) 106 (47.7) 480 (72.2) <0.0001
Number of ED visits post diagno-
sis, mean (SD)
2.9 (2.1) 2.3 (1.4) 1.7 (1.6) 2.4 (1.8) <0.0001
Chemotherapy in the first year post
diagnosis, n (%)
60 (27.1) 138 (62.2) 193 (86.9) 391 (58.8) <0.0001
Number of chemotherapy visits,
mean (SD)
9.5 (4.0) 10.9 (5.6) 11.3 (5.4) 10.9 (5.3) 0.0674
Statistically significant differences in (unadjusted) survival over time were observed for concor-
dance score terciles (p-value < 0.0001, Figure 6).
Table 3 summarizes the association between concordance and survival for both unadjusted and
adjusted Cox models with both categorical and continuous measures for the concordance score.
The unadjusted Cox model found a significant effect of pathway concordance on survival, with
decreased risk of mortality associated with having higher values of the concordance score in both
the continuous (HR = 0.72, 95% CI = (0.66, 0.79)) and categorical models (HR = 0.51, 95% CI
= (0.36, 0.73) for Medium vs. Low tercile; HR = 0.31, 95% CI = (0.20, 0.47) for High vs. Low
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Figure 6 Kaplan-Meier curves for each concordance score tercile
Table 3 Risk of mortality associated with concordance score for categorical and continuous models
Unadjusted Adjusted
HR 95% CI p-value HR 95% CI p-value
Categorical
ω (Med. vs Low) 0.51 (0.36, 0.73) 0.0002 0.70 (0.48, 1.03) 0.0684
ω (High vs Low) 0.31 (0.20, 0.47) <0.0001 0.57 (0.36, 0.92) 0.0216
Continuous ω (unit change) 0.72 (0.66, 0.79) <0.0001 0.80 (0.71, 0.90) 0.0003
tercile). Note that a unit change in the continuous model is scaled to represent a change of 0.1 in
ω(xˆ).
Along with concordance score, the adjusted Cox regression included age, sex, rural residency,
number of outpatient visits a year prior to diagnosis, screening group, cancer stage and grade,
emergent surgery status, and length of hospital stay following the surgery. A nonlinear relationship
between three covariates (age, number of outpatient visits, and length of hospital stay following the
surgical treatment) was observed, so restricted cubic splines with three knots were used to model
these covariates. No violation of model assumptions was detected. Results of the adjusted analyses
showed statistical significance for the association between the concordance score and mortality.
Similar to the unadjusted model, there was a significant effect of concordance on survival in the
continuous model, with decreased risk of mortality associated with higher values of the concordance
score (HR = 0.80, 95% CI = (0.71, 0.90)). However, only the High vs. Low tercile difference was
significant (HR = 0.57, 95% CI = (0.36, 0.92)) for the categorical model.
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Figure 7 Forest plot of variable effects in continuous Cox regression model with 95% confidence intervals
Figure 7 summarizes the influence of each covariate in the adjusted continuous Cox model on
survival. A hazard ratio below (above) 1 indicates a beneficial (harmful) effect on survival. If the
confidence interval contains 1, the effect is not statistically significant at the 0.05 level. Concordance
score and female sex have a statistically significant beneficial effect on survival, while cancer stage,
cancer grade and emergent surgery have significant harmful effects. The corresponding figure for
the adjusted categorical Cox model is provided in Appendix E.
Model validation with 1000 bootstrap resamples showed acceptable coefficient shrinkage (0.84)
and model optimism (C-statistic reduction by 0.024), indicating minor evidence of overfitting.
Based on the average of the bootstrap samples, we estimated a bias of -0.003 for the concordance
score coefficient (log(HR) = −0.2207 or HR = 0.802 in our model versus log(HR) = −0.2237 or
HR = 0.799 for the average of the bootstrap samples). The empirical confidence intervals of the
concordance score estimates had similar coverage (0.70, 0.92) as the confidence intervals from the
original model. The results of resampling imply model consistency in estimating the effect of the
inverse optimization-based concordance score.
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Table 4 Risk of mortality associated with concordance score for categorical and continuous models using the
cost vector from reference pathway only model (IOref(Xˆ r))
Unadjusted Adjusted
HR 95% CI p-value HR 95% CI p-value
Categorical
ω (Med. vs Low) 0.66 (0.46, 0.94) 0.0215 1.07 (0.72, 1.60) 0.7239
ω (High vs Low) 0.52 (0.36, 0.77) 0.0008 1.01 (0.65, 1.58) 0.9518
Continuous ω (unit change) 0.75 (0.66, 0.86) <0.0001 0.94 (0.81, 1.10) 0.4477
7.3. The Value of Patient Data
Finally, we repeat the above survival analysis using a cost vector (and associated concordance
metric) that is derived from the model with only reference pathways as input (IOref(Xˆ r)) in order
to quantify the value of our data-driven approach that uses patient pathway data to supplement
the reference pathways. We focus on the Cox models (both categorical and continuous) and use
the same methodological approach and dataset.
Table 4 summarizes the association between concordance and survival based on the reference-
only cost vector. Similar to the data-driven approach, the unadjusted Cox model found a significant
effect of pathway concordance on survival in both the continuous (HR = 0.75, 95% CI = (0.66,
0.86)) and categorical models (HR = 0.66, 95% CI = (0.46, 0.94) for Medium vs. Low tercile; HR
= 0.52, 95% CI = (0.36, 0.77) for High vs. Low tercile). However, after adjusting for other relevant
covariates, the association weakened significantly. In particular, there is no longer any significant
association between concordance score and survival for both the categorical or continuous models.
For illustrative purposes, we include the forest plot for only the continuous model in Appendix E.
Overall, this analysis shows that a data-driven approach, using patient data to refine the cost
vector so alignment with patient outcomes is improved, produces a pathway concordance met-
ric that is much more relevant and statistically meaningful for population-based health outcome
monitoring.
8. Conclusions
This paper proposes the first data-driven inverse optimization approach to measuring pathway con-
cordance in any problem context. Our specific development focuses on clinical pathway concordance
for cancer patients. We model the care network as a directed graph and use both recommended
pathways and actual patient pathways to develop and refine a novel pathway concordance metric.
We confirm the value of our data-driven approach by showing that the concordance scores are
strongly associated with survival for patients with stage III colon cancer, even after adjusting for
other patient covariates.
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In contrast to previous work in clinical pathway concordance, which focus on single events
or courses of treatment by patients in a single institution, our concordance score can support
population-level health system monitoring and reporting. Given its statistically significant asso-
ciation with clinical outcomes, our metric provides meaningful quantitative measures of system
efficiency and variation. Improving concordance measurement in a data-driven and generalizable
manner allows officials to evaluate complex practice patterns at the population level and describe
clinical (e.g., survival) and system (e.g., cost) outcomes in relation to variation in care. These rich
data can then be explored for providing decision support to clinicians and health system admin-
istrators. Measuring pathway concordance may help identify gaps and bottlenecks in the health
system, facilitate modeling of system changes and resulting costs, and allow for inter-jurisdictional
comparison while accommodating system differences. These activities, in turn, can help support
planning and priority setting. Concordance metrics optimized for clinical outcomes are also useful
in promoting and implementing best practice, helping providers focus on appropriate interventions
and reduce inappropriate resource use. These topics are the focus of future work, where concor-
dance measurement will be explored to identify opportunities for improvement along the entire
care continuum and among different patient populations.
Our methodological contribution includes a two-stage inverse optimization approach to han-
dling primary and secondary data sources, as well as a model that tries to separate good and bad
(secondary) data points as much as possible. These methodological advances, motivated by our
real-world problem context, suggest avenues for future research in inverse optimization. To keep
our models tractable, temporal aspects of concordance measurement were accounted for in how
we processed the event logs to form patient pathways. Future work may also consider modify-
ing the clinical activity network so the state space captured by the nodes also include temporal
characteristics, such as receipt of treatment before or after a certain time frame.
Appendix A: Proofs
Proof of Lemma 1. Since the objective function has a lower bound of zero, it suffices to show that
IOref(Xˆ r) is feasible if and only if there are at least two distinct paths from the start node (denoted s) to
the end node (denoted t).
(⇐) Let P1 and P2 be two distinct paths from s to t. Let P1 \P2 = {(i, j)∈A| (i, j)∈ P1 and (i, j) /∈ P2} and
P2 \P1 = {(i, j)∈A| (i, j)∈ P2 and (i, j) /∈ P1}. If we set cij =−1 for (i, j)∈ P1 \P2, cij = 1 for (i, j)∈ P2 \P1,
and cij = 0 for all the other arcs in the network, then c satisfies ‖c‖∞ = 1 and Ac = 0. Note that P1 is the
shortest path for the designed cost vector c which has finite total cost. From strong duality, its dual is also
optimal meaning that there exists a p that satisfies constraint A′p ≤ c for c. Finally, we build a feasible
solution for IOref(Xˆ r) by setting rq = c′xˆrq −b′p for q= 1, . . . ,R.
(⇒) Suppose to the contrary that there is only one path from s to t, which means the entire network itself
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is the path from s to t. Since there is a feasible c, there is some arc (i, j) with cost |cij |= 1. The constraint
Ac = 0 implies that the incoming arc to i and outgoing arc from j also has cost equal to 1 in absolute value.
Continuing this logic, the same will be true of the outgoing arc from s, but this violates Ac = 0, meaning c
cannot be feasible. 
Proof of Proposition 1. The dual of FO(c∗) is feasible since c∗ and p∗ satisfy the dual feasibility condi-
tions. Hence, FO(c∗) is not unbounded, implying no negative cost cycles. 
Proof of Proposition 2. Let (c∗,p∗,r∗) be an optimal solution to IOref(Xˆ r). We can construct a feasible
solution to IOpat(Xˆ s, Xˆ d,r∗) by setting sq = c∗′xˆsq − b′p∗ for q = 1, . . . , S and dq = c∗′xˆdq − b′p∗ for q =
1, . . . ,D. Hence, what remains is to show that the objective is bounded. Substituting the third and fourth
constraints into the objective, we have
D
S
S∑
q=1
sq −
D∑
q=1
dq =
D
S
(
S∑
q=1
c′xˆsq −Sb′p
)
−
(
D∑
q=1
c′xˆdq −Db′p
)
=
D
S
S∑
q=1
c′xˆsq −
D∑
q=1
c′xˆdq ,
which is clearly bounded below since xˆsq and xˆ
d
q are data and ‖c‖∞ = 1. In particular, if M =
maxq,q′{‖xˆsq‖,‖xˆdq′‖}, then by Holder’s inequality the absolute value of the objective is bounded by 2DM .

Proof of Theorem 1. 1. Given Xˆ r and ct, t = 1, . . . , T , the denominator term in ρ(Xˆ r) is fixed. An
optimal solution to IOref(Xˆ r), by definition of its objective function, minimizes the numerator of 1−ρ(Xˆ r),
thus maximizing ρ(Xˆ r).
2. It is clear that ρ(Xˆ r)≤ 1 since 1−ρ(Xˆ r) is the ratio of sums of squares, which are nonnegative. To show
ρ(Xˆ r)≥ 0, note that ∑Rq=1 (c∗′xˆrq − c∗′x∗)2 ≤∑Rq=1 (c′txˆrq − c′txt)2 for all t because ct is a feasible solution
to IOref(Xˆ r).
3. An optimal solution to IOref(k)(Xˆ r) is feasible for IOref(k+1)(Xˆ r), since the latter problem is a relaxation
of the former. Invoking the first statement in this theorem, ρ(k)(Xˆ r)≤ ρ(k+1)(Xˆ r). 
Proof of Theorem 2. Note that M(xˆ)≥ c∗′xˆ≥ c∗′x∗, where the first inequality is by definition of M(xˆ)
and second inequality is by optimality of x∗. It is straightforward to then show that 0 ≤ ω(xˆ) ≤ 1, with
equality at the lower or upper bound when the first or second inequalities above on c∗′xˆ, respectively, are
tight. 
Appendix B: Lower-Dimensional Transformation for ρ Calculation
Because m< n and A ∈R(m−1)×n has rank m− 1, we can partition A to two matrices B and N in which
B is a square matrix comprising the linear independent columns of A while N comprises the remaining
columns of A (Bertsekas 1999). We denote the corresponding decomposition of x and c by [xB;xN ] and
[cB;cN ], respectively. Substituting xB = B
−1(b−NxN ) in the shortest path problem transforms the feasible
region to a lower dimensional space where z = xN ∈ Rn−(m−1) is the variable, and the feasible region is
represented by inequality constraints only: min
z
{d′z +C : B−1Nz≤B−1b,z≥ 0} where d = cN − cBB−1N
and C = cBB
−1b. The transformed problem is a full-dimensional problem in dimension n− (m− 1).
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Appendix C: Calculation of Longest Walk Length M(xˆ)
We use the Bellman-Ford equations to calculate the longest walk for walks up to a given length N . Let the
node set be N , the start node be s, and the end node be t. Let C(v, k) be the cost of the longest walk from
s to v ∈N that takes k steps, computed via backward induction over the equations
C(v, k) = max
u∈N
{C(u,k− 1) + c(u, v)}, k= 2, . . . ,N, v ∈N ,
C(s,1) = 0,
C(v,1) =∞, v 6= s,
where c(u, v) = cuv if (u, v) ∈ A, and c(u, v) =∞ otherwise. We solve this system of equations once up to
a value of N that equals the length of the longest patient pathway (maxq,q′{‖xˆsq‖,‖xˆdq′‖}). Then, the costs
of the longest walks with length for each integer up to N are stored and can simply be looked up when
computing ω(xˆ) for each patient pathway.
Appendix D: Data Sources
• Cancer Care Ontario
— Ontario Cancer Registry (OCR)
— Collaborative Stage Dataset (CSI)
— Colonoscopy Interim Reporting Tool (CIRT)
— Lab Reporting Tool (LRT)
— Screening HUB
— Activity Level Reporting (ALR)
• Ministry of Health and Long-Term Care (MoHLTC)
— Registered Persons Database (RPDB)
— Ontario Health Insurance Plan (OHIP) Claims
• Canadian Institute for Health Information (CIHI)
— National Ambulatory Care Reporting System (NACRS)
— Discharge Abstract Database (DAD)
• Statistics Canada
— Postal Code Conversion file (PCCF+6B)
Appendix E: Supplementary Figures for Survival Analysis
Figure 8 summarizes the influence of each covariate in the adjusted categorical Cox model from Section 7.2
on survival. Figure 9 depicts a similar forest plot, but for the adjusted continuous Cox model with the
concordance score based on the reference pathway-only model from Section 7.3.
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